Melatonin and cerium oxide nanoparticles additively mitigate capecitabine-induced hepatotoxicity via targeting oxidative stress, apoptosis, and ERK signaling Authors: Khalid M. Mohany, Heba M. Elkady, Nashwa Hamad, Sahar E.M. El-Deek Published: 2026 ABSTRACT BackgroundCapecitabine (CAP), a chemotherapy prodrug, is associated with a significant dose-limiting hepatotoxicity. This study evaluated the protective efficacy of melatonin (MEL) and cerium oxide nanoparticles (CeO₂ NPs) against CAP-induced toxicity.MethodsFifty male Wistar rats were divided into five groups: control, CAP-only (500 mg/kg/week), CAP + MEL (10 mg/kg/day), CAP + CeO₂ NPs (30 mg/kg/day), and a combination therapy group (CAP + MEL + CeO₂ NPs). After a six-week treatment period, assessments included alanine and aspartate transaminases (ALT, AST); hepatic oxidative stress markers [glutathione peroxidase-1 (GPx-1), superoxide dismutase (SOD), and malondialdehyde (MDA)]; apoptotic markers [B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (BAX) mRNA, cleaved caspase-3 (c-caspase-3), and protein 53 (p53)]; pro-survival signaling [extracellular signal-regulated kinase (ERK1/2)]; and histopathological evaluation of liver tissue.ResultsCAP administration induced significant liver damage, characterized by elevated ALT and AST, depletion of GPx-1 and SOD, increased MDA, and activation of the mitochondrial apoptotic pathway, indicated by an elevated BAX/Bcl-2 ratio and increased levels of p53 and c-caspase-3. This was accompanied by suppression of ERK1/2 signaling and severe histopathological alterations. Both MEL and CeO₂ NPs, significantly attenuated these deleterious effects. The combination therapy demonstrated a comparatively superior effect, resulting in a near-complete normalization of all measured parameters, including oxidative stress, apoptosis, ERK1/2 activity, and liver histoarchitecture.ConclusionMelatonin and CeO₂ NPs provide hepatoprotection via distinct yet complementary mechanisms. Their combined administration presents a superior strategy to mitigate CAP-induced liver injury by concurrently counteracting oxidative stress, inhibiting apoptosis, and enhancing pro-survival signaling.Supplementary InformationThe online version contains supplementary material available at 10.1186/s40360-026-01150-y. Introduction Capecitabine (CAP) is an oral prodrug used in the management of metastatic breast and colorectal cancers. It undergoes enzymatic conversion to its active metabolite, 5-fluorouracil (5-FU), a process that occurs predominantly in the liver [1]. Although this activation is intended to target malignant cells, the hepatic tissue itself is vulnerable to the cytotoxic effects of 5-FU intermediates, resulting in drug-induced liver injury. This hepatotoxicity is primarily mediated by a cascade of oxidative stress, inflammatory responses, and programmed cell death, clinically presenting as elevated serum transaminases, hyperbilirubinemia, and, in severe instances, hepatic failure [2, 3]. Identifying strategies to counteract this hepatic damage is crucial for enhancing the safety and tolerability of CAP-based regimens. One promising approach involves the use of compounds with known cytoprotective properties. Melatonin (MEL), an endogenous indoleamine, possesses potent antioxidant and anti-inflammatory activities [4]. Its hepatoprotective efficacy has been demonstrated across multiple experimental models of liver injury, including carbon tetrachloride (CCl₄)-induced hepatotoxicity [5], aflatoxin B₁ exposure [6], ethanol-induced liver damage [7, 8], and cadmium toxicity [9]. These protective actions include direct free radical scavenging and upregulation of antioxidant enzymes such as superoxide dismutase (SOD) and glutathione peroxidase (GPx). Furthermore, melatonin exerts anti-apoptotic effects by regulating the balance of pro- and anti-apoptotic proteins, such as B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X protein (BAX) [10, 11]. Given that CAP-induced hepatotoxicity is primarily mediated by oxidative stress and mitochondrial apoptotic signaling pathways effectively targeted by melatonin in other toxin models, we hypothesized that melatonin would confer similar protection against CAP-induced hepatic injury. One study reported that melatonin ameliorated CAP-induced hepatorenal toxicity by attenuating oxidative stress, reducing transaminases, blood urea, serum creatinine, and histopathological injury, while restoring antioxidant capacity. Adjunctive melatonin may offer chemoprotection during capecitabine therapy [12]. Concurrently, cerium oxide nanoparticles (CeO₂ NPs), or nanoceria, have gained attention for their unique regenerative antioxidant capacity. Their capacity to alternate between Ce³⁺ and Ce⁴⁺ oxidation states allows them to mimic catalytic enzymes, providing sustained protection against oxidative stress. Preclinical studies have documented the hepatoprotective potential of CeO₂ NPs in diverse models of liver injury, where they attenuate lipid peroxidation, suppress inflammatory mediators, and support cellular survival [13, 14].The CeO₂ NPs ameliorates thioacetamide- and acetaminophen-induced hepatotoxicity by reducing oxidative stress, inflammation, and apoptosis while enhancing antioxidants and hepatocellular regeneration [15, 16]. While melatonin has shown protective effects against capecitabine (CAP)-induced toxicity and CeO₂ NPs have demonstrated hepatoprotective properties in other models of liver injury, no study to date has investigated whether these two agents can act additively to mitigate CAP-induced hepatotoxicity. Therefore, the present study aimed to determine whether melatonin and CeO₂ NPs, individually or in combination, could attenuate CAP-induced liver injury. Our investigation comprehensively evaluated liver function by assessing (i) serum markers of hepatocellular injury [transaminase (ALT) and aspartate transaminase (AST)] and hepatic synthetic function (total protein, albumin); (ii) metabolic parameters including fasting blood glucose (FBG), glycated hemoglobin (HbA1c%), and lipid profile [total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), and triacylglycerols (TAG)]; (iii) hepatic oxidative stress markers (GPx-1, SOD, MDA); (iv) apoptotic regulators [Bcl-2, BAX mRNA, cleaved caspase-2 (c-caspase-3), and and protein 53 (p53)]; and (v) the pro-survival extracellular signal-regulated kinase (ERK1/2) signaling pathway. Histopathological examination of liver tissue was also performed to provide structural correlation with the biochemical findings. Materials and methods Ethical approval The study was conducted in strict accordance with international ethical guidelines for the care and use of laboratory animals. The research protocol was reviewed and approved by the Research Ethics Committee of the Faculty of Pharmacy, Assiut University (IRB# 05-2025-04). Sample size calculation A priori power analysis was conducted using G*Power software to determine the appropriate sample size. Based on serum ALT data from a previous study on capecitabine-induced hepatotoxicity [12], an effect size of 0.65 was calculated. With an alpha level of 0.05, desired power of 0.85, and five experimental groups, the analysis indicated that eight rats per group were required. To account for potential attrition and ensure robust statistical power for multiple comparisons, the sample size was increased to ten animals per group, consistent with the resource equation method [17]. Animals and housing Male Wistar rats, with an average initial weight of 180 ± 20 g, were obtained from the animal housing unit, Assiut University. The animals were maintained under standard laboratory conditions, including a controlled ambient temperature (20–25 °C), humidity, and a 12-hour light/dark cycle. Adequate ventilation and regular cage sanitation were provided to ensure a hygienic environment. All rats had unrestricted access to a standard commercial rodent diet and fresh water throughout the study duration. Chemicals and reagents CAP (purity ≥ 98%, product code SML0653) and MEL powder (purity ≥ 98%) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Physicochemical characterization of CeO2NPs: The CeO₂ NPs) were obtained commercially from Nano Gate (Nasr City, Cairo, Egypt; product code NG-CeO2-20). Physicochemical characterization data were provided by the manufacturer after Calvache-Muñoz et al. [18], briefly: Imaging was conducted using a JEOL JEM-2100 high-resolution transmission electron microscope (JEOL Ltd., Tokyo, Japan) at an accelerating voltage of 200 kV. The nanoparticles exhibited a spherical morphology with a mean diameter of 18.5 ± 3.2 nm (size distribution: 12–25 nm). This size range aligns with previously reported values for ceria nanoparticles synthesized through comparable methods [18].Examination using a Zeiss Sigma 500 VP field emission scanning electron microscope (Carl Zeiss AG, Oberkochen, Germany) at 5 kV accelerating voltage confirmed uniform spherical morphology and the absence of substantial particle aggregation.Hydrodynamic diameter and surface charge measurements were performed using a Malvern Zetasizer Nano ZS (Malvern Instruments, UK). In sterile normal saline, the average hydrodynamic diameter was 45.7 ± 5.1 nm (polydispersity index: 0.156), with a zeta potential of + 32.4 ± 2.8 mV, indicative of favorable colloidal stability.Crystallographic analysis was carried out on a Bruker D8 Advance X-ray diffractometer (Bruker Corporation, USA) employing Cu-Kα radiation (λ = 1.5406 Å) across a 2θ range of 20–80°. The diffraction pattern displayed characteristic reflections corresponding to the cubic fluorite structure of CeO₂ (JCPDS card No. 34–0394), with no evidence of secondary crystalline phases. The crystallite size, estimated using the Scherrer equation, was approximately 16.2 nm, consistent with TEM findings and published data for phase-pure CeO₂ nanoparticles [18].Elemental composition was assessed using an Oxford Instruments X-Max⁽ᴺ⁾ EDX detector coupled to the SEM. Spectra confirmed cerium and oxygen as the principal constituents, with a Ce: O atomic ratio consistent with CeO₂ stoichiometry.Spectra were acquired on a Thermo Scientific Nicolet iS10 FT-IR spectrometer over the 400–4000 cm⁻¹ range. Analysis revealed characteristic Ce-O stretching vibrations at approximately 450 cm⁻¹, corresponding to the infrared-active vibrational mode of the fluorite structure, with no detectable organic surface contaminants.Absorption measurements were performed using a Thermo Scientific Genesys 6 UV-vis spectrophotometer across 200–800 nm. The nanoparticles exhibited a prominent absorption band with a maximum at approximately 330 nm, attributed to the O²⁻ → Ce⁴⁺ charge transfer transition. This finding is consistent with reported bandgap values (3.8 eV and 3.4 eV) for ceria nanoparticles [18].Diffuse reflectance spectra were recorded on a JASCO V-670 UV-vis-NIR spectrophotometer. The Kubelka-Munk function was applied to determine the optical bandgap, which was calculated to be approximately 3.4 eV, suggesting the presence of Ce³⁺-associated mid-gap states as previously documented [18].Specific surface area was determined via nitrogen adsorption-desorption isotherms using a Quantachrome Nova 2200e surface area analyzer. The measured BET surface area was 85.3 m²/g, consistent with the nanoscale dimensions of the particles.Purity assessment was conducted on a PerkinElmer Optima 8300 Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES). Cerium content was determined to be 87.2% by mass, with trace metal impurities comprising less than 0.1% of the total mass. Imaging was conducted using a JEOL JEM-2100 high-resolution transmission electron microscope (JEOL Ltd., Tokyo, Japan) at an accelerating voltage of 200 kV. The nanoparticles exhibited a spherical morphology with a mean diameter of 18.5 ± 3.2 nm (size distribution: 12–25 nm). This size range aligns with previously reported values for ceria nanoparticles synthesized through comparable methods [18]. Imaging was conducted using a JEOL JEM-2100 high-resolution transmission electron microscope (JEOL Ltd., Tokyo, Japan) at an accelerating voltage of 200 kV. The nanoparticles exhibited a spherical morphology with a mean diameter of 18.5 ± 3.2 nm (size distribution: 12–25 nm). This size range aligns with previously reported values for ceria nanoparticles synthesized through comparable methods [18]. Examination using a Zeiss Sigma 500 VP field emission scanning electron microscope (Carl Zeiss AG, Oberkochen, Germany) at 5 kV accelerating voltage confirmed uniform spherical morphology and the absence of substantial particle aggregation. Examination using a Zeiss Sigma 500 VP field emission scanning electron microscope (Carl Zeiss AG, Oberkochen, Germany) at 5 kV accelerating voltage confirmed uniform spherical morphology and the absence of substantial particle aggregation. Hydrodynamic diameter and surface charge measurements were performed using a Malvern Zetasizer Nano ZS (Malvern Instruments, UK). In sterile normal saline, the average hydrodynamic diameter was 45.7 ± 5.1 nm (polydispersity index: 0.156), with a zeta potential of + 32.4 ± 2.8 mV, indicative of favorable colloidal stability. Hydrodynamic diameter and surface charge measurements were performed using a Malvern Zetasizer Nano ZS (Malvern Instruments, UK). In sterile normal saline, the average hydrodynamic diameter was 45.7 ± 5.1 nm (polydispersity index: 0.156), with a zeta potential of + 32.4 ± 2.8 mV, indicative of favorable colloidal stability. Crystallographic analysis was carried out on a Bruker D8 Advance X-ray diffractometer (Bruker Corporation, USA) employing Cu-Kα radiation (λ = 1.5406 Å) across a 2θ range of 20–80°. The diffraction pattern displayed characteristic reflections corresponding to the cubic fluorite structure of CeO₂ (JCPDS card No. 34–0394), with no evidence of secondary crystalline phases. The crystallite size, estimated using the Scherrer equation, was approximately 16.2 nm, consistent with TEM findings and published data for phase-pure CeO₂ nanoparticles [18]. Crystallographic analysis was carried out on a Bruker D8 Advance X-ray diffractometer (Bruker Corporation, USA) employing Cu-Kα radiation (λ = 1.5406 Å) across a 2θ range of 20–80°. The diffraction pattern displayed characteristic reflections corresponding to the cubic fluorite structure of CeO₂ (JCPDS card No. 34–0394), with no evidence of secondary crystalline phases. The crystallite size, estimated using the Scherrer equation, was approximately 16.2 nm, consistent with TEM findings and published data for phase-pure CeO₂ nanoparticles [18]. Elemental composition was assessed using an Oxford Instruments X-Max⁽ᴺ⁾ EDX detector coupled to the SEM. Spectra confirmed cerium and oxygen as the principal constituents, with a Ce: O atomic ratio consistent with CeO₂ stoichiometry. Elemental composition was assessed using an Oxford Instruments X-Max⁽ᴺ⁾ EDX detector coupled to the SEM. Spectra confirmed cerium and oxygen as the principal constituents, with a Ce: O atomic ratio consistent with CeO₂ stoichiometry. Spectra were acquired on a Thermo Scientific Nicolet iS10 FT-IR spectrometer over the 400–4000 cm⁻¹ range. Analysis revealed characteristic Ce-O stretching vibrations at approximately 450 cm⁻¹, corresponding to the infrared-active vibrational mode of the fluorite structure, with no detectable organic surface contaminants. Spectra were acquired on a Thermo Scientific Nicolet iS10 FT-IR spectrometer over the 400–4000 cm⁻¹ range. Analysis revealed characteristic Ce-O stretching vibrations at approximately 450 cm⁻¹, corresponding to the infrared-active vibrational mode of the fluorite structure, with no detectable organic surface contaminants. Absorption measurements were performed using a Thermo Scientific Genesys 6 UV-vis spectrophotometer across 200–800 nm. The nanoparticles exhibited a prominent absorption band with a maximum at approximately 330 nm, attributed to the O²⁻ → Ce⁴⁺ charge transfer transition. This finding is consistent with reported bandgap values (3.8 eV and 3.4 eV) for ceria nanoparticles [18]. Absorption measurements were performed using a Thermo Scientific Genesys 6 UV-vis spectrophotometer across 200–800 nm. The nanoparticles exhibited a prominent absorption band with a maximum at approximately 330 nm, attributed to the O²⁻ → Ce⁴⁺ charge transfer transition. This finding is consistent with reported bandgap values (3.8 eV and 3.4 eV) for ceria nanoparticles [18]. Diffuse reflectance spectra were recorded on a JASCO V-670 UV-vis-NIR spectrophotometer. The Kubelka-Munk function was applied to determine the optical bandgap, which was calculated to be approximately 3.4 eV, suggesting the presence of Ce³⁺-associated mid-gap states as previously documented [18]. Diffuse reflectance spectra were recorded on a JASCO V-670 UV-vis-NIR spectrophotometer. The Kubelka-Munk function was applied to determine the optical bandgap, which was calculated to be approximately 3.4 eV, suggesting the presence of Ce³⁺-associated mid-gap states as previously documented [18]. Specific surface area was determined via nitrogen adsorption-desorption isotherms using a Quantachrome Nova 2200e surface area analyzer. The measured BET surface area was 85.3 m²/g, consistent with the nanoscale dimensions of the particles. Specific surface area was determined via nitrogen adsorption-desorption isotherms using a Quantachrome Nova 2200e surface area analyzer. The measured BET surface area was 85.3 m²/g, consistent with the nanoscale dimensions of the particles. Purity assessment was conducted on a PerkinElmer Optima 8300 Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES). Cerium content was determined to be 87.2% by mass, with trace metal impurities comprising less than 0.1% of the total mass. Purity assessment was conducted on a PerkinElmer Optima 8300 Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES). Cerium content was determined to be 87.2% by mass, with trace metal impurities comprising less than 0.1% of the total mass. Nanoparticles were employed without further modification. Prior to in vivo administration, CeO₂ NPs were dispersed in sterile normal saline via ultrasonication (Branson Sonifier SFX250, 20 kHz, 40% amplitude) for 15 min to achieve a homogeneous suspension. Experimental design and treatment protocol Following a one-week acclimatization period, the rats were randomly allocated into five experimental groups, with ten animals per group, for a six-week intervention. Group 1 (G1) served as the control and received daily intraperitoneal (IP) injections of 1 mL normal saline. Group 2 (G2) administered a weekly IP injection of CAP at a dose of 500 mg/kg [12]. Group 3 (G3) received the same weekly CAP regimen as G2, supplemented with a daily IP injection of MEL at 10 mg/kg [12]. Group 4 (G4) was treated with the weekly CAP dose plus a daily IP injection of CeO₂ NPs at 30 mg/kg [15]. Finally, Group 5 (G5) received the weekly CAP regimen along with daily co-administration of both MEL (10 mg/kg) and CeO₂ NPs (30 mg/kg) via IP injection (administered as two separate injections at the same time). Blood and tissue sample collection At the end of the six-week treatment period, animals were fasted overnight prior to terminal procedures. For blood and tissue collection, rats were deeply anesthetized with a single intraperitoneal injection of urethane (1.2 g/kg body weight, prepared as a 20% w/v solution in sterile normal saline). Urethane was specifically selected for this terminal procedure based on its well-established pharmacological profile in rats, where it produces prolonged surgical-plane anesthesia with minimal suppression of cardiovascular and respiratory reflexes -critical factors for maintaining physiological stability during cardiac puncture and ensuring high-quality blood and tissue samples [19, 20]. Importantly, urethane is accepted for non-recovery (terminal) procedures in rats where extended anesthesia is required, as it avoids the need for repeated anesthetic administration. All animals were euthanized immediately after blood collection while still under deep anesthesia, ensuring they never recovered consciousness [21]. Upon confirmation of anesthesia, blood samples were collected via cardiac puncture, allowed to clot, and centrifuged at 4000 rpm for 10 min to separate serum. The serum was aliquoted and stored for subsequent biochemical analysis. Fasting serum glucose (FBG) levels were measured using a colorimetric glucose oxidase kit (Abcam, Cat# ab219924). Glycated hemoglobin (HbA1c%) was quantified with a commercial ion-exchange resin kit from N.S Biotic Co. (Alexandria, Egypt). The serum lipid profile, comprising total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), and triacylglycerols (TAG), was assessed colorimetrically using corresponding kits (Spectrum Diagnostic, Egypt; Cat# 230003, 266002, and 314003, respectively). Low-density lipoprotein cholesterol (LDL-c) concentration was derived using the Friedewald calculation [22]. Total protein was quantified with the Pierce™ BCA Protein Assay Kit (ThermoFisher Scientific, Cat# 23227), while serum albumin was determined via a bromocresol green method (Sigma-Aldrich, Cat# RAB0603). Finally, the levels of the liver enzymes (ALT and AST) were measured colorimetrically using specific assay kits (Sigma-Aldrich, Cat# MAK052 and MAK055, respectively). Following blood collection, euthanasia was performed by decapitation. Liver tissues were rapidly excised. Each liver was divided into four aliquots: one was homogenized for oxidative stress marker analysis, a second was snap-frozen for RNA extraction, a third was preserved for protein extraction, and a fourth was fixed in formalin for histopathological examination [12]. Estimation of hepatic oxidative stress biomarkers Pre-weighed liver tissue samples were homogenized on ice in cold phosphate buffer (0.05 M, pH 7.0) to prepare a 10% (w/v) homogenate. The homogenates were centrifuged at 4000 rpm for 10 min, and the resulting supernatants were collected and stored at -20 °C. The total protein concentration in the supernatants was quantified using the Bradford assay [23]. The activities of the antioxidant enzymes GPx-1 and SOD were assessed using commercially available ELISA kits (Abcam, UK; ab102530 and ab65354, respectively), following the manufacturers’ protocols. The extent of lipid peroxidation was determined by measuring malondialdehyde (MDA) levels using the thiobarbituric acid reactive substances (TBARS) assay. In this method, MDA reacts with thiobarbituric acid under high temperature and acidic conditions to form a pink chromophore, the absorbance of which was measured at 535 nm [24]. Quantitative real-time PCR (qRT-PCR) analysis for hepatic Bcl-2 and BAX mRNA expression Total RNA was isolated from snap-frozen liver tissue using Trizol reagent (Invitrogen, UK) according to the standard protocol [25, 26]. RNA concentration and purity were determined spectrophotometrically, and samples with an A260/A280 ratio between 1.9 and 2.1 were used for cDNA synthesis. For each sample, 1 µg of total RNA was reverse-transcribed into complementary DNA (cDNA) using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) with a blend of oligo(dT) and random hexamer primers [27]. qRT-PCR amplification was performed on a StepOnePlus Real-Time PCR System (ThermoFisher Scientific) using SYBR Green Master Mix. All reactions were performed in triplicate to ensure reliability. The primer sequences used for amplification were as follows: for the reference gene GAPDH, the forward primer was 5′-CTTTCGTCCGCCAGGTGAA-3′ and the reverse was 5′-AGGGCCCCAATACACCGAAA-3′; for the target gene BAX, the forward primer was 5′-GCGGACTGATGTCCCTGTCTCC-3′ and the reverse was 5′-AAAGATGGTCACGGTCTGCCCA-3′; and for the target gene Bcl-2, the forward primer was 5′-GAACTGGTACGGCCCCAGCAT-3′ and the reverse was 5′-GGGGCAGGCATGTTGACTTC-3′.The thermal cycling conditions consisted of an initial denaturation at 95 °C for 8 min, followed by 40 cycles of denaturation (95 °C for 40 s), annealing (52 °C for 30 s), and extension (72 °C for 40 s), with a final elongation at 72 °C for 7 min. Relative mRNA expression levels were calculated using the 2−ΔΔCt method, with GAPDH serving as the endogenous control for normalization [28]. Western blot analysis for hepatic c-caspase-3, P53, and ERK1/2 Following primary antibodies were used: rabbit monoclonal anti-cleaved caspase-3 (Abcam, ab32042), rabbit polyclonal anti-p53 (Cell Signaling Technology, #9282), and mouse monoclonal anti-ERK1/2 (Santa Cruz Biotechnology, sc-514302). Horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (Abcam, ab6721) and rabbit anti-mouse IgG (Abcam, ab6728) were used as secondary antibodies. The Enhanced Chemiluminescent (ECL) substrate was from ThermoFisher Scientific. Method Liver tissue samples were lysed in ice-cold RIPA buffer supplemented with protease and phosphatase inhibitors (1 µg/ml leupeptin, 1 µg/ml aprotinin, 0.5 mM PMSF, 1 mM Na₃VO₄, and 5 mM NaF). The lysates were centrifuged at 3000 rpm for 10 min at 4 °C, and the supernatant was collected. Protein concentration was determined by the Bradford assay. Subsequently, 40 µg of protein from each sample were separated by 10% SDS-PAGE and transferred to nitrocellulose membranes. The membranes were blocked with 5% skimmed milk and then incubated with the respective primary antibodies for 3 h at room temperature. After washing, the membranes were incubated with the appropriate HRP-conjugated secondary antibodies for 1 h. Immunoreactive bands were visualized using an ECL substrate. To ensure equal loading, membranes were stripped and re-probed with an anti-β-actin antibody. Band intensity was quantified densitometrically using ImageJ software and normalized to β-actin levels [29, 30]. Hepatic histopathological analysis Liver specimens were fixed in 10% neutral buffered formalin, processed through a graded ethanol series for dehydration, cleared in xylene, and embedded in paraffin blocks. Serial sections of 5 μm thickness were cut and stained with hematoxylin and eosin (H&E). The stained sections were examined under a light microscope (Olympus CX31, Tokyo, Japan) equipped with a digital camera for image capture. A standardized histopathological scoring system was applied to evaluate the severity and incidence of lesions across all experimental groups [31]. Statistical analysis Data are reported as mean ± SD and were analyzed using SPSS (v26.0). Significance among the five experimental groups was determined by one-way ANOVA, with subsequent multiple comparisons performed using Tukey’s post-hoc test. Statistical significance was set at p < 0.05. Results Metabolic and liver function Rats treated with CAP (G2) developed significant liver injury relative to the control group (G1), as demonstrated by a marked elevation in serum ALT and AST levels, alongside a pronounced reduction in total serum proteins and albumin (Table 1). CAP administration also significantly lowered serum HDL-c and elevated serum LDL-c. Both MEL (G3) and CeO₂ NPs (G4) effectively counteracted this CAP-induced hepatic damage. In the MEL-treated group (G3), serum transaminases (ALT and AST) were significantly reduced compared to the CAP-only group (G2), restoring them to levels comparable to the control. However, hepatic synthetic function parameters—specifically total serum proteins and albumin—showed only partial recovery; while they were significantly higher than in G2, they remained significantly lower than control values (p < 0.05 vs. G1). Treatment with CeO₂ NPs alone (G4) also produced a significant hepatoprotective effect, notably normalizing the increased serum ALT and AST concentrations to near-baseline values and significantly improving serum proteins and albumin compared to G2. The combination therapy (G5) exhibited the most potent hepatoprotective effects. All parameters, including transaminases, total protein, albumin, and lipid fractions, were significantly improved compared to the CAP-treated group (G2) and were maintained at levels like those observed in the control group (G1) (Table 1). Table 1Glycemic and lipid profiles and hepatic functionsG1:[n = 10]G2[n = 10]G3[n = 10]G4[n = 10]G5[n = 10]p-ValueFBG (mg/dl)87.5 ± 11.6100.6 ± 11.387.1 ± 11.988.2 ± 15.195.5 ± 10.10.0590.020 #0.921#0.017*0.898#0.027*0.840^0.148#0.353*0.129^0.186@HbA1c%5.2 ± 0.35.6 ± 0.35.2 ± 0.35.2 ± 0.45.4 ± 0.30.0600.021#0.943#0.029*0.902#0.038*0.831^0.142#0.371*0.124^0.178@s-TAG (mg/dl)99.4 ± 13.8112.6 ± 19.2117.3 ± 16.1105.1 ± 11.5110.4 ± 19.40.1460.077#0.019#0.522*0.438#0.309*0.101^0.138#0.764*0.349^0.471@s-TC (mg/dl)150.2 ± 18.1168.1 ± 7.6161.9 ± 15.2159.7 ± 17.0151.7 ± 22.40.1180.024#0.126#0.413*0.212#0.269*0.771^0.843#0.034*0.181^0.292@s-HDL-c (mg/dl)51.9 ± 3.336.7 ± 3.742.6 ± 3.146.0 ± 3.345.3 ± 2.7< 0.001< 0.001#< 0.001#< 0.001*< 0.001#< 0.001*0.026^< 0.001#< 0.001*0.074^0.637@s-LDL-c (mg/dl)78.4 ± 17.2108.8 ± 11.295.8 ± 17.792.6 ± 17.584.3 ± 23.20.005< 0.001#0.034#0.108*0.080#0.048*0.693^0.462#0.003*0.155^0.299@s-ALT (U/l)24.3 ± 4.889.6 ± 24.530.8 ± 8.225.3 ± 7.627.5 ± 7.5< 0.001< 0.001#0.263#< 0.001*0.861#< 0.001*0.343^0.482#< 0.001*0.565^0.706@s-AST (U/l)23.4 ± 3.894.8 ± 52.129.8 ± 6.928.1 ± 6.325.5 ± 7.5< 0.001< 0.001#0.533#< 0.001*0.666#< 0.001*0.872^0.841#< 0.001*0.694^0.817@s-protein (gm/dl)6.9 ± 0.44.8 ± 0.55.6 ± 0.46.1 ± 0.46.1 ± 0.3< 0.001< 0.001#< 0.001#< 0.001*< 0.001#< 0.001*0.026^< 0.001#< 0.001*0.074^0.637@s-Alb (gm/dl)4.7 ± 0.33.3 ± 0.33.8 ± 0.34.2 ± 0.34.1 ± 0.4< 0.001< 0.001#< 0.001#< 0.001*< 0.001#< 0.001*0.039^< 0.001#< 0.001*0.082^0.721@The values are presented as mean ± SD, G1: control group, G2: treated with CAP, G3: treated with CAP and MEL, G4: treated with CAP and CeO2 NPs, G5: treated with CAP, MEL and CeO2 NPs, FBG: fasting blood glucose, HbA1c%: glycated hemoglobin percentage, s-TAG: serum triacylglycerol, s-TC: serum total cholesterol, s-HDL-c: serum high density lipoprotein cholesterol, s-LDL-c: serum low density lipoprotein cholesterol, s-ALT: serum alanine transaminase, s-protein: Total serum proteins, s-Alb: serum albumin level. #Significance against G1, *Significance against G2, ^Significance against G3, @Significance against G4 Table 1Glycemic and lipid profiles and hepatic functionsG1:[n = 10]G2[n = 10]G3[n = 10]G4[n = 10]G5[n = 10]p-ValueFBG (mg/dl)87.5 ± 11.6100.6 ± 11.387.1 ± 11.988.2 ± 15.195.5 ± 10.10.0590.020 #0.921#0.017*0.898#0.027*0.840^0.148#0.353*0.129^0.186@HbA1c%5.2 ± 0.35.6 ± 0.35.2 ± 0.35.2 ± 0.45.4 ± 0.30.0600.021#0.943#0.029*0.902#0.038*0.831^0.142#0.371*0.124^0.178@s-TAG (mg/dl)99.4 ± 13.8112.6 ± 19.2117.3 ± 16.1105.1 ± 11.5110.4 ± 19.40.1460.077#0.019#0.522*0.438#0.309*0.101^0.138#0.764*0.349^0.471@s-TC (mg/dl)150.2 ± 18.1168.1 ± 7.6161.9 ± 15.2159.7 ± 17.0151.7 ± 22.40.1180.024#0.126#0.413*0.212#0.269*0.771^0.843#0.034*0.181^0.292@s-HDL-c (mg/dl)51.9 ± 3.336.7 ± 3.742.6 ± 3.146.0 ± 3.345.3 ± 2.7< 0.001< 0.001#< 0.001#< 0.001*< 0.001#< 0.001*0.026^< 0.001#< 0.001*0.074^0.637@s-LDL-c (mg/dl)78.4 ± 17.2108.8 ± 11.295.8 ± 17.792.6 ± 17.584.3 ± 23.20.005< 0.001#0.034#0.108*0.080#0.048*0.693^0.462#0.003*0.155^0.299@s-ALT (U/l)24.3 ± 4.889.6 ± 24.530.8 ± 8.225.3 ± 7.627.5 ± 7.5< 0.001< 0.001#0.263#< 0.001*0.861#< 0.001*0.343^0.482#< 0.001*0.565^0.706@s-AST (U/l)23.4 ± 3.894.8 ± 52.129.8 ± 6.928.1 ± 6.325.5 ± 7.5< 0.001< 0.001#0.533#< 0.001*0.666#< 0.001*0.872^0.841#< 0.001*0.694^0.817@s-protein (gm/dl)6.9 ± 0.44.8 ± 0.55.6 ± 0.46.1 ± 0.46.1 ± 0.3< 0.001< 0.001#< 0.001#< 0.001*< 0.001#< 0.001*0.026^< 0.001#< 0.001*0.074^0.637@s-Alb (gm/dl)4.7 ± 0.33.3 ± 0.33.8 ± 0.34.2 ± 0.34.1 ± 0.4< 0.001< 0.001#< 0.001#< 0.001*< 0.001#< 0.001*0.039^< 0.001#< 0.001*0.082^0.721@The values are presented as mean ± SD, G1: control group, G2: treated with CAP, G3: treated with CAP and MEL, G4: treated with CAP and CeO2 NPs, G5: treated with CAP, MEL and CeO2 NPs, FBG: fasting blood glucose, HbA1c%: glycated hemoglobin percentage, s-TAG: serum triacylglycerol, s-TC: serum total cholesterol, s-HDL-c: serum high density lipoprotein cholesterol, s-LDL-c: serum low density lipoprotein cholesterol, s-ALT: serum alanine transaminase, s-protein: Total serum proteins, s-Alb: serum albumin level. #Significance against G1, *Significance against G2, ^Significance against G3, @Significance against G4 Glycemic and lipid profiles and hepatic functions 0.921# 0.017* 0.898# 0.027* 0.840^ 0.148# 0.353* 0.129^ 0.186@ 0.943# 0.029* 0.902# 0.038* 0.831^ 0.142# 0.371* 0.124^ 0.178@ 0.019# 0.522* 0.438# 0.309* 0.101^ 0.138# 0.764* 0.349^ 0.471@ 0.126# 0.413* 0.212# 0.269* 0.771^ 0.843# 0.034* 0.181^ 0.292@ < 0.001# < 0.001* < 0.001# < 0.001* 0.026^ < 0.001# < 0.001* 0.074^ 0.637@ 0.034# 0.108* 0.080# 0.048* 0.693^ 0.462# 0.003* 0.155^ 0.299@ 0.263# < 0.001* 0.861# < 0.001* 0.343^ 0.482# < 0.001* 0.565^ 0.706@ 0.533# < 0.001* 0.666# < 0.001* 0.872^ 0.841# < 0.001* 0.694^ 0.817@ < 0.001# < 0.001* < 0.001# < 0.001* 0.026^ < 0.001# < 0.001* 0.074^ 0.637@ < 0.001# < 0.001* < 0.001# < 0.001* 0.039^ < 0.001# < 0.001* 0.082^ 0.721@ The values are presented as mean ± SD, G1: control group, G2: treated with CAP, G3: treated with CAP and MEL, G4: treated with CAP and CeO2 NPs, G5: treated with CAP, MEL and CeO2 NPs, FBG: fasting blood glucose, HbA1c%: glycated hemoglobin percentage, s-TAG: serum triacylglycerol, s-TC: serum total cholesterol, s-HDL-c: serum high density lipoprotein cholesterol, s-LDL-c: serum low density lipoprotein cholesterol, s-ALT: serum alanine transaminase, s-protein: Total serum proteins, s-Alb: serum albumin level. #Significance against G1, *Significance against G2, ^Significance against G3, @Significance against G4 Hepatic oxidative stress biomarkers Administration of CAP induced a significant suppression of key hepatic antioxidant enzymes, namely GPx-1 and SOD, relative to the control group. This depletion reflects a compromised endogenous defense system against drug-induced reactive oxygen species (ROS). Concurrently, a marked increase in hepatic MDA levels was observed, confirming substantial lipid peroxidation and oxidative cellular injury (Table 2). These findings collectively demonstrate that CAP treatment instigates a state of profound oxidative stress and hepatic damage (Table 2). Coadministration of MEL with CAP (G3) significantly attenuated the CAP-induced oxidative alterations. The treatment significantly restored the activities of GPx-1 and SOD and substantially lowered MDA levels, returning these parameters to near-normal levels. A comparable protective effect was observed with CeO₂ NPs (G4), which also effectively reversed the CAP-induced decline in antioxidant enzyme activities and the rise in lipid peroxidation (Table 2). The most comprehensive protection was afforded by the combination therapy (G5). This group exhibited a near-complete normalization of the oxidative stress profile, with GPx-1 and SOD activities and MDA concentrations restored to levels statistically nonsignificant from the control group (Table 2). Table 2Hepatic oxidative stress biomarkersG1:[n = 10]G2[n = 10]G3[n = 10]G4[n = 10]G5[n = 10]Overallp-ValueGPx-1 (pg/mg TTP)109.5 ± 6.176.4 ± 19.588.7 ± 20.5101.9 ± 17.3105.2 ± 6.5< 0.001< 0.001#0.004#0.082*0.274#0.001*0.062^0.537#< 0.001*0.021^0.631@SOD (ng/ mg TTP)3.1 ± 0.51.7 ± 0.12.7 ± 0.12.7 ± 0.82.9 ± 0.8< 0.001< 0.001#0.160#< 0.001*0.199#< 0.001*0.900^0.502#< 0.001*0.546^0.535@MDA (ng/ mg TTP)197.6 ± 27.4324.9 ± 54.5202.3 ± 43.8189.8 ± 20.9187.3 ± 24.7< 0.001< 0.001#0.777#< 0.001*0.636#< 0.001*0.450^0.532#< 0.001*0.365^0.880@The values are presented as mean ± SD, G1: control group, G2: treated with CAP, G3: treated with CAP and MEL, G4: treated with CAP and CeO2 NPs, G5: treated with CAP, MEL and CeO2 NPs, GPx-1: Glutathione peroxidase-1, TTP: Total tissue protein, SOD: Superoxide dismutase, MDA: Malondialdehyde. #Significance against G1, *Significance against G2, ^Significance against G3, @Significance against G4 Table 2Hepatic oxidative stress biomarkersG1:[n = 10]G2[n = 10]G3[n = 10]G4[n = 10]G5[n = 10]Overallp-ValueGPx-1 (pg/mg TTP)109.5 ± 6.176.4 ± 19.588.7 ± 20.5101.9 ± 17.3105.2 ± 6.5< 0.001< 0.001#0.004#0.082*0.274#0.001*0.062^0.537#< 0.001*0.021^0.631@SOD (ng/ mg TTP)3.1 ± 0.51.7 ± 0.12.7 ± 0.12.7 ± 0.82.9 ± 0.8< 0.001< 0.001#0.160#< 0.001*0.199#< 0.001*0.900^0.502#< 0.001*0.546^0.535@MDA (ng/ mg TTP)197.6 ± 27.4324.9 ± 54.5202.3 ± 43.8189.8 ± 20.9187.3 ± 24.7< 0.001< 0.001#0.777#< 0.001*0.636#< 0.001*0.450^0.532#< 0.001*0.365^0.880@The values are presented as mean ± SD, G1: control group, G2: treated with CAP, G3: treated with CAP and MEL, G4: treated with CAP and CeO2 NPs, G5: treated with CAP, MEL and CeO2 NPs, GPx-1: Glutathione peroxidase-1, TTP: Total tissue protein, SOD: Superoxide dismutase, MDA: Malondialdehyde. #Significance against G1, *Significance against G2, ^Significance against G3, @Significance against G4 Hepatic oxidative stress biomarkers 0.004# 0.082* 0.274# 0.001* 0.062^ 0.537# < 0.001* 0.021^ 0.631@ 0.160# < 0.001* 0.199# < 0.001* 0.900^ 0.502# < 0.001* 0.546^ 0.535@ 0.777# < 0.001* 0.636# < 0.001* 0.450^ 0.532# < 0.001* 0.365^ 0.880@ The values are presented as mean ± SD, G1: control group, G2: treated with CAP, G3: treated with CAP and MEL, G4: treated with CAP and CeO2 NPs, G5: treated with CAP, MEL and CeO2 NPs, GPx-1: Glutathione peroxidase-1, TTP: Total tissue protein, SOD: Superoxide dismutase, MDA: Malondialdehyde. #Significance against G1, *Significance against G2, ^Significance against G3, @Significance against G4 Hepatic Bcl-2 and BAX mRNA expression Administration of CAP (G2) significantly downregulated anti-apoptotic Bcl-2 mRNA and substantially upregulated pro-apoptotic BAX mRNA compared to the control group (G1). This resultant shift in the BAX/Bcl-2 ratio signifies an activation of the mitochondrial apoptotic pathway in the liver, aligning with the cytotoxic action of CAP (Table 3). Coadministration of MEL with CAP (G3) conferred significant protection against CAP-induced changes, significantly reducing BAX mRNA expression and improving Bcl-2 mRNA levels relative to the CAP-only group (G2) (Table 3). A similar robust protective effect was observed in the CeO₂ NPs group (G4), where BAX mRNA was suppressed and Bcl-2 mRNA was elevated, with both parameters approaching control values (Table 3). The most potent anti-apoptotic outcome was achieved in the combination therapy group (G5). This group demonstrated a near-complete normalization of the apoptotic markers, with BAX mRNA expression suppressed to a level comparable to the control baseline and Bcl-2 mRNA expression largely restored. This superior effect suggests a potential interaction between MEL and CeO₂ NPs in counteracting CAP-induced apoptotic signaling more effectively than either monotherapy (Table 3). Table 3Hepatic apoptotic markersG1:[n = 10]G2[n = 10]G3[n = 10]G4[n = 10]G5[n = 10]Overallp-ValueBAX mRNA RE1.0 ± 0.076.0 ± 1.92.9 ± 1.62.5 ± 1.11.7 ± 0.8< 0.001< 0.001#0.002#< 0.001*0.012#< 0.001*0.528^0.236#< 0.001*0.045^0.162@BCL-2 mRNA RE1.06 ± 0.040.6 ± 0.040.8 ± 0.060.8 ± 0.070.9 ± 0.08< 0.001< 0.001#< 0.001#< 0.001*< 0.001#< 0.001*0.270^< 0.001#< 0.001*0.537^0.089@The values are presented as mean ± SD, G1: control group, G2: treated with CAP, G3: treated with CAP and MEL, G4: treated with CAP and CeO2 NPs, G5: treated with CAP, MEL and CeO2 NPs, BAX mRNA RE: BAX mRNA relative expression, Bcl-2 mRNA RE: Bcl-2 mRNA relative expression. #Significance against G1, *Significance against G2, ^Significance against G3, @Significance against G4 Table 3Hepatic apoptotic markersG1:[n = 10]G2[n = 10]G3[n = 10]G4[n = 10]G5[n = 10]Overallp-ValueBAX mRNA RE1.0 ± 0.076.0 ± 1.92.9 ± 1.62.5 ± 1.11.7 ± 0.8< 0.001< 0.001#0.002#< 0.001*0.012#< 0.001*0.528^0.236#< 0.001*0.045^0.162@BCL-2 mRNA RE1.06 ± 0.040.6 ± 0.040.8 ± 0.060.8 ± 0.070.9 ± 0.08< 0.001< 0.001#< 0.001#< 0.001*< 0.001#< 0.001*0.270^< 0.001#< 0.001*0.537^0.089@The values are presented as mean ± SD, G1: control group, G2: treated with CAP, G3: treated with CAP and MEL, G4: treated with CAP and CeO2 NPs, G5: treated with CAP, MEL and CeO2 NPs, BAX mRNA RE: BAX mRNA relative expression, Bcl-2 mRNA RE: Bcl-2 mRNA relative expression. #Significance against G1, *Significance against G2, ^Significance against G3, @Significance against G4 Hepatic apoptotic markers 0.002# < 0.001* 0.012# < 0.001* 0.528^ 0.236# < 0.001* 0.045^ 0.162@ < 0.001# < 0.001* < 0.001# < 0.001* 0.270^ < 0.001# < 0.001* 0.537^ 0.089@ The values are presented as mean ± SD, G1: control group, G2: treated with CAP, G3: treated with CAP and MEL, G4: treated with CAP and CeO2 NPs, G5: treated with CAP, MEL and CeO2 NPs, BAX mRNA RE: BAX mRNA relative expression, Bcl-2 mRNA RE: Bcl-2 mRNA relative expression. #Significance against G1, *Significance against G2, ^Significance against G3, @Significance against G4 Hepatic c-caspase-3, P53, and ERK levels Administration of CAP (G2) resulted in a significant increase in c-caspase-3 levels in liver tissue compared to the control group (G1). This elevation was attenuated by concurrent treatment with MEL (G3), CeO₂ NPs (G4), or their combination (G5), with the most pronounced reduction observed in groups G4 and G5, respectively (Fig. 1a). Similarly, CAP treatment (G2) significantly elevated p53 levels relative to the control (G1). Co-administration of MEL (G3), CeO₂ NPs (G4), or both (G5) mitigated this increase to varying degrees, with the most substantial reduction achieved by the combination therapy in G5 (Fig. 1b). Conversely, CAP (G2) induced a marked suppression of ERK1 and ERK2 levels (total ERK expression, not activation status). This suppression was effectively reversed in the treatment groups (G3, G4, G5), where ERK levels were restored to near-baseline or higher (Fig. 1c). Fig. 1Relative levels of (a) c-caspase-3 (b) P53 and (c) ERK in liver samples. G1: control group, G2: treated with CAP, G3: treated with CAP and MEL, G4: treated with CAP and CeO2 NPs, G5: treated with CAP, MEL and CeO2 NPs Relative levels of (a) c-caspase-3 (b) P53 and (c) ERK in liver samples. G1: control group, G2: treated with CAP, G3: treated with CAP and MEL, G4: treated with CAP and CeO2 NPs, G5: treated with CAP, MEL and CeO2 NPs Histopathological findings Table 4 demonstrated histopathological lesion score in the examined hepatic tissue sections of all groups. Table 4Histopathological score and incidence of the recoreded liver lesions in all groupsLesionG1G2G3G4G5Vascular congestion− (0%)+++(100%)++(40%)+(30%)− (0%)Fatty degeneration of heptocytes− (0%)+(100%)− (0%)− (0%)− (0%)Vacuolar degeneration of heptocytes− (0%)+++(100%)+(30%)+(40%)− (0%)Coagulative necrosis of heptocytes− (0%)+++(90%)+(30%)− (0%)− (0%)Perivascular mononuclear cells infiltration− (0%)+++(100%)+(50%)− (0%)− (0%)Lesion severity is scored as: (–) absent (0% of the tissue section affected); (+) mild (5–25% affected); (++) moderate (26–50% affected); (+++) severe (≥ 50% affected). For each group (n = 10), the severity symbol represents the maximal grade observed among the animals that exhibited the lesion. The incidence percentage in parentheses indicates the proportion of animals per group that showed the lesion at any grade; the remaining animals were completely free of that specific lesion (scored as “–“). G1: control group, G2: treated with CAP, G3: treated with CAP and MEL, G4: treated with CAP and CeO2 NPs, G5: treated with CAP, MEL and CeO2 NPs Table 4Histopathological score and incidence of the recoreded liver lesions in all groupsLesionG1G2G3G4G5Vascular congestion− (0%)+++(100%)++(40%)+(30%)− (0%)Fatty degeneration of heptocytes− (0%)+(100%)− (0%)− (0%)− (0%)Vacuolar degeneration of heptocytes− (0%)+++(100%)+(30%)+(40%)− (0%)Coagulative necrosis of heptocytes− (0%)+++(90%)+(30%)− (0%)− (0%)Perivascular mononuclear cells infiltration− (0%)+++(100%)+(50%)− (0%)− (0%)Lesion severity is scored as: (–) absent (0% of the tissue section affected); (+) mild (5–25% affected); (++) moderate (26–50% affected); (+++) severe (≥ 50% affected). For each group (n = 10), the severity symbol represents the maximal grade observed among the animals that exhibited the lesion. The incidence percentage in parentheses indicates the proportion of animals per group that showed the lesion at any grade; the remaining animals were completely free of that specific lesion (scored as “–“). G1: control group, G2: treated with CAP, G3: treated with CAP and MEL, G4: treated with CAP and CeO2 NPs, G5: treated with CAP, MEL and CeO2 NPs Histopathological score and incidence of the recoreded liver lesions in all groups Lesion severity is scored as: (–) absent (0% of the tissue section affected); (+) mild (5–25% affected); (++) moderate (26–50% affected); (+++) severe (≥ 50% affected). For each group (n = 10), the severity symbol represents the maximal grade observed among the animals that exhibited the lesion. The incidence percentage in parentheses indicates the proportion of animals per group that showed the lesion at any grade; the remaining animals were completely free of that specific lesion (scored as “–“). G1: control group, G2: treated with CAP, G3: treated with CAP and MEL, G4: treated with CAP and CeO2 NPs, G5: treated with CAP, MEL and CeO2 NPs Histopathological examination of hepatic tissue sections revealed normal central veins, hepatocytes, blood sinusoids, and portal areas in control rats (Fig. 2a). In contrast, the CAP-treated group (G2) exhibited marked pathological alterations, including congestion of central veins, hepatocyte karyomegaly, diffuse vacuolar degeneration, focal coagulative necrosis, fatty degeneration, and perivascular mononuclear cell infiltration (Fig. 2b-d). Coadministration of MEL (G3) or CeO₂ NPs (G4) with CAP resulted in significant histological improvement, though minor lesions persisted. Residual changes in G3 included dilated central veins and blood sinusoids, slight vacuolar degeneration, sporadic hepatocyte necrosis, and focal perivascular mononuclear cell infiltration (Fig. 2e, f). The G4 group showed only slight central vein congestion and minor hepatocyte vacuolar degeneration (Fig. 2g). Notably, the combination therapy group (G5) demonstrated apparently normal hepatic histoarchitecture, comparable to the controls (Fig. 2h). Fig. 2Photomicrograph of hepatic tissues of all experimental groups. (a): G1 (control group), (b-d): G2 (treated with CAP), (e, f): G3 (treated with CAP and MEL), (g): G4 (treated with CAP and CeO2 NPs), and (h): G5 (treated with CAP, MEL and CeO2 NPs). (cv) normally appeared central vein, (s) normal blood sinusoids, (blue asterisk) congested central vein, (curved arrow) fatty degeneration of hepatocytes, (red arrowhead) slightly enlarged nuclei (karyomegaly), (black arrowhead) vacuolar degeneration of hepatocytes, (arrow) coagulative necrosis, (black asterisk) perivascular mononuclear cells infiltration, and (wavy arrow) dilated blood sinusoids. H&E, bar= 20 μm Photomicrograph of hepatic tissues of all experimental groups. (a): G1 (control group), (b-d): G2 (treated with CAP), (e, f): G3 (treated with CAP and MEL), (g): G4 (treated with CAP and CeO2 NPs), and (h): G5 (treated with CAP, MEL and CeO2 NPs). (cv) normally appeared central vein, (s) normal blood sinusoids, (blue asterisk) congested central vein, (curved arrow) fatty degeneration of hepatocytes, (red arrowhead) slightly enlarged nuclei (karyomegaly), (black arrowhead) vacuolar degeneration of hepatocytes, (arrow) coagulative necrosis, (black asterisk) perivascular mononuclear cells infiltration, and (wavy arrow) dilated blood sinusoids. H&E, bar= 20 μm Discussion The management of CAP-induced hepatotoxicity remains a significant clinical challenge, as dose-limiting liver injury can compromise the therapeutic efficacy of this widely used chemotherapeutic agent. While the hepatoprotective properties of MEL and CeO₂ NPs have been individually documented in various toxin models, the potential for their combined, additive action against CAP-specific liver injury had not been previously investigated. The present study was designed to address this critical gap. Our findings demonstrate that both MEL and CeO₂ NPs, when administered individually, significantly attenuate CAP-induced hepatocellular damage. More importantly, this study provides the first evidence that their combination yields a comparatively superior protective effect. This enhanced efficacy is achieved through the concurrent and comprehensive restoration of the endogenous antioxidant defense system, near-complete suppression of the mitochondrial apoptotic cascade, and robust reactivation of the pro-survival ERK1/2 signaling pathway, culminating in the preservation of normal hepatic architecture. Biochemical and metabolic disturbances Administration of CAP induced a characteristic pattern of hepatocellular injury, evidenced by significantly elevated serum transaminases (ALT and AST), reflecting compromised hepatocyte membrane integrity associated with both necrotic and apoptotic cell death. This cytotoxicity is attributable to the intracellular metabolism of CAP to 5-FU and its active metabolites, which disrupt nucleic acid synthesis via thymidylate synthase inhibition and erroneous incorporation into RNA and DNA. Concurrent reductions in total serum protein and albumin concentrations indicate marked impairment of hepatic synthetic function. Given that albumin synthesis occurs predominantly in the rough endoplasmic reticulum—an organelle particularly susceptible to oxidative and metabolic stress—its dysfunction during CAP treatment likely underlies the observed decrease in these critical plasma proteins [2, 32, 33]. Beyond its impact on synthetic function, CAP disrupted lipid homeostasis, as evidenced by significantly reduced HDL-c and elevated LDL-c levels. This dyslipidemic effect may result from CAP-induced inhibition of enzymes such as lipoprotein lipase or from broader metabolic adaptations to hepatic stress. Such lipid alterations represent an underrecognized component of CAP toxicity, with potential implications for cardiovascular health in patients receiving prolonged therapy [34, 35]. Oxidative stress as the central mechanism The central mechanism underlying CAP-induced hepatotoxicity involves profound oxidative stress initiated by its metabolic activation. Generated 5-FU metabolites disrupt the mitochondrial electron transport chain, promoting electron leakage and superoxide anion (O₂•⁻) generation [36]. Our data demonstrate that CAP significantly compromised hepatic antioxidant defenses, evidenced by marked depletion of GPx-1 and SOD. SOD catalyzes O₂•⁻ dismutation to hydrogen peroxide (H₂O₂), while GPx-1 subsequently detoxifies H₂O₂ and lipid hydroperoxides. Enzyme depletion likely results from exhaustive consumption neutralizing CAP-driven ROS and possible oxidative inactivation of active sites. This antioxidant collapse permits ROS accumulation, confirmed by elevated MDA, a terminal product of polyunsaturated fatty acid peroxidation. The resulting oxidative damage affects cellular membranes, proteins, and DNA while triggering programmed cell death [36, 37]. Apoptotic signaling and cell death Our investigation confirms that CAP-induced oxidative stress is a potent driver of the intrinsic (mitochondrial) apoptotic pathway. The significant upregulation of pro-apoptotic BAX mRNA and concurrent downregulation of anti-apoptotic Bcl-2 mRNA indicate a decisive transcriptional shift toward cell death. Oxidative stress promotes the activation and mitochondrial translocation of cytosolic BAX, where it oligomerizes to form pores, while simultaneously inactivating Bcl-2. This altered BAX/Bcl-2 ratio facilitates mitochondrial outer membrane permeabilization (MOMP), triggering the release of cytochrome c into the cytosol. Cytochrome c then binds to Apaf-1, forming the apoptosome complex, which activates initiator caspase-9. This molecular cascade is definitively corroborated by our western blot analysis, which showed a substantial increase in cleaved caspase-3 (c-caspase-3), the key executioner protease that leads to the systematic cleavage of cellular substrates and apoptotic demise [38, 39]. Furthermore, the significant elevation of the tumor suppressor protein p53 suggests an activation of the DNA damage response pathway. ROS can directly cause DNA strand breaks, while 5-FU metabolites inhibit DNA synthesis, both triggering p53 stabilization and nuclear translocation. p53 then acts as a transcription factor, further amplifying BAX expression and repressing Bcl-2, thereby reinforcing the mitochondrial apoptotic signal [40]. Conversely, the significant reduction in total ERK1/2 protein levels may indicate suppression of the MAPK/ERK pro-survival pathway, though this interpretation is limited by the absence of phosphorylated ERK measurements (the active form). Oxidative stress can inactivate upstream kinases in this pathway, potentially tilting the cellular balance away from proliferation and repair and toward death [41, 42]. The severe histopathological lesions observed -including vascular congestion, vacuolar degeneration, coagulative necrosis, and inflammatory infiltration- represent the structural culmination of this orchestrated biochemical and molecular collapse [43, 44]. Efficacy of MEL and CeO₂ NPs Against this backdrop of CAP-induced injury, the protective efficacy of both MEL and CeO₂ NPs is notable and can be attributed to their distinct yet complementary mechanisms. MEL exhibited a multi-faceted protective strategy. As a potent, broad-spectrum antioxidant, it directly scavenges various ROS, including the highly damaging hydroxyl radical (•OH). More importantly, it indirectly enhances the endogenous defense system by upregulating the gene expression and activities of antioxidant enzymes such as GPx-1 and SOD. This “indirect antioxidant” action likely occurs through the activation of specific transcription factors via its membrane receptor-mediated signaling. This robust antioxidant effect translated into a powerful anti-apoptotic outcome. MEL is known to inhibit mitochondrial permeability transition pore opening, thereby stabilizing the mitochondrial membrane potential and preventing cytochrome c release. This mechanism explains the observed normalization of the BAX/Bcl-2 ratio, the reduction in c-caspase-3, and the downregulation of p53. The improvement in ERK1/2 levels further indicates a restoration of pro-survival signaling, facilitated by the mitigation of the oxidative environment that had suppressed it [45, 46]. Similarly, CeO₂ NPs (G4) exhibited a powerful protective profile rooted in their unique nanozyme like properties. Their efficacy is attributed to the presence of mixed valence states (Ce³⁺ and Ce⁴⁺) on their surface, which enables them to mimic the activities of both SOD and catalase in a regenerative, catalytic cycle. They catalytically dismutate O₂•⁻ into H₂O₂ and subsequently decompose H₂O₂ into water and oxygen. This enzyme-mimetic activity provides a robust, persistent, and enzyme-independent defense against the primary ROS, which explains the potent restoration of antioxidant balance and the consequent suppression of the downstream apoptotic cascade and p53 activation [47, 48]. The pronounced histological improvement, with an absence of severe lesions like fatty degeneration and coagulative necrosis, underscores the efficacy of this catalytic scavenging. Superiority of combined therapy The most compelling evidence from this study emerges from the combined therapy group (G5), which demonstrated near-complete normalization of all measured parameters and hepatic architecture. This superior protection can be explained by a complementary multi-targeted defense system. We propose a model wherein MEL acts as a first responder and signal modulator, directly neutralizing radicals and upregulating the host’s enzymatic defenses, while simultaneously providing direct mitochondrial stabilization. Concurrently, CeO₂ NPs function as a persistent, catalytic ROS-scavenging engine, continuously degrading ROS without being consumed, thereby reducing the burden on the endogenous enzyme systems. This coordinated action creates a more robust and resilient antioxidant network. By more effectively quenching the initial oxidative burst, the combination therapy more potently prevents the activation of the p53-mediated DNA damage response, the BAX-driven mitochondrial apoptosis initiation, and the suppression of ERK survival signaling. The restoration of ERK not only to baseline but to elevated levels in G5 suggests an active pro-regenerative environment, likely because the combined therapy most effectively eliminated the oxidative blockade on this pathway. The apparently normal hepatic histoarchitecture in G5 is the ultimate testament to the success of this superior strategy in preserving cellular integrity. Conclusion CAP-induced liver injury is primarily driven by oxidative stress, leading to disruption of redox homeostasis, lipid peroxidation, and activation of the mitochondrial apoptotic pathway. The present study demonstrates that both melatonin and cerium oxide nanoparticles confer significant hepatoprotection against CAP-induced toxicity when administered concurrently as preventive interventions. Melatonin exerts its protective effects through direct free radical scavenging and upregulation of endogenous antioxidant enzymes, while CeO₂ NPs function as regenerative nanozymes with sustained SOD- and catalase-mimetic activities. Their combination produced comparatively superior normalization of oxidative stress markers, apoptotic regulators (BAX/Bcl-2 ratio, c-caspase-3, p53), and hepatic histoarchitecture relative to either agent alone. Limitations of the study As a preclinical study utilizing a rodent model, its findings cannot be directly extrapolated to human patients, underscoring the necessity for subsequent validation in large-scale clinical studies. Additionally, the determination of safe and efficacious dosing protocols for both MEL and CeO₂ NPs in humans represents a critical step that remains unresolved. Finally, although our results highlight pivotal mechanistic pathways, a more comprehensive molecular-level analysis is imperative to fully delineate the hepatoprotective mechanisms employed against CAP-induced liver injury. Also, this study did not include a CeO₂ NPs-only control group, as extensive published literature and our preliminary toxicity screening demonstrated no significant inherent physiological effects at the employed dose. However, we acknowledge that inclusion of this group would have further strengthened the reliability of our conclusions regarding nanoparticle-specific protective effects. Future studies should incorporate this control to definitively isolate protective from intrinsic effects. Moreover, Future work should prioritize independent, in-house characterization to ensure result consistency and facilitate cross-study comparisons rather than relying on data sourced from manufacturer specifications. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1